Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways

Area of Science:

• Virology
• Molecular Biology
• Oncology

Background:

• Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) is an oncogene implicated in EBV-associated tumors.
• Sequence variations in LMP-1 may alter its oncogenic functions.
• Previous studies primarily focused on prototype B95.8 and nasopharyngeal carcinoma (NPC)-derived LMP-1.

Purpose of the Study:

• To investigate the signaling functions of LMP-1 from diverse EBV isolates.
• To correlate LMP-1 sequence variations with its functional activities.
• To understand the complexity of LMP-1 sequence variation and its impact on EBV-associated diseases.

Main Methods:

• Analyzed signaling functions of LMP-1 from nine EBV isolates, including European variants (Groups A-D) and Chinese NPC-derived LMP-1.
• Assessed activation of transcription factors NF-kappa B, AP-1, and STAT.
• Measured induction of CD54 (intercellular adhesion molecule 1) protein expression.

Main Results:

• Chinese and Group D LMP-1 variants showed significantly higher NF-kappa B activation compared to B95.8.
• Chinese, Group B, and Group D variants demonstrated enhanced AP-1 activation.
• STAT activation was consistent across all tested LMP-1 variants, irrespective of sequence variation in the proposed Janus kinase 3 binding region.
• CD54 induction differences did not correlate with NF-kappa B or AP-1 activation levels.

Conclusions:

• Defined LMP-1 sequence variant groups correlate with specific signaling functions.
• The relationship between LMP-1 sequence variation and signaling is highly complex.
• It is unlikely that a single amino acid substitution or deletion defines a disease-associated LMP-1 variant.